(Q36750711)

16 August 2017

1 reference

title

Vaccine adjuvants revisited (English)

1 reference

16 August 2017

1 reference

Aguilar JC

1

1 reference

PubMed ID

17336431

16 August 2017

Rodríguez EG

series ordinal

2

1 reference

PubMed ID

17336431

16 August 2017

language of work or name

English

0 references

publication date

16 February 2007

1 reference

16 August 2017

1 reference

16 August 2017

25

1 reference

16 August 2017

3752-3762

1 reference

16 August 2017

19

1 reference

Vaccine adjuvants: current state and future trends

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Antigen sampling across epithelial barriers and induction of mucosal immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

An update on vaccine adjuvants in clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Immunological adjuvants: Desirable properties and side-effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Intussusception among infants given an oral rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Advantages of Aluminium Hydroxide Adsorbed Combined Diphtheria, Tetanus, and Pertussis Vaccines for the Immunization of Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Adjuvants: current status, clinical perspectives and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Adjuvants for human vaccines--current status, problems and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Natural and synthetic trehalose diesters as immunomodulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Response to influenza vaccine in adjuvant 65-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Ten-Year Follow-Up Study for Safety of Adjuvant 65 Influenza Vaccine in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Antibody responses and resistance to challenge in volunteers vaccinated with live attenuated, detergent split and oil adjuvant A2-Hong Kong-68 (H 3 N 2 ) influenza vaccines. A report to the Medical Research Council Committee on Influenza and other R

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Antibody response and reactions to aqueous influenza vaccine, simple emulsion vaccine and multiple emulsion vaccine. A report to the Medical Research Council Committee on influenza and other respiratory virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Peptide vaccines derived from a malarial surface antigen: effects of dose and adjuvants on immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Immunity in response to particulate antigen-delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Particulate delivery systems for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Liposomes as immunological adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

The adjuvant properties of liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

7 January 2021

New aspects of liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Use of liposomes as biodegradable and harmless adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

The 'co-delivery' approach to liposomal vaccines: application to the development of influenza-A and hepatitis-B vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Biodegradable microspheres as a vaccine delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Systemic immune responses in sheep, induced by a novel nano-bead adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

ISCOMATRIX adjuvant for antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Achieving directed immunostimulating complexes incorporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Saponin-adjuvanted particulate vaccines for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Transcutaneous vaccination with virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: preparation and in vitro properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

The adjuvanticity of Algammulin, a new vaccine adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

CpG motifs in bacterial DNA and their immune effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Methylated CpG-containing plasmid activates the immune system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Immunotherapeutic uses of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Superior activity of the type C class of ISS in vitro and in vivo across multiple species.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Enhanced cell-mediated IFN-gamma-secreting activity against the HIV-1IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backbone engineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

New hope for an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Liposomal preparations of muramyl glycopeptides as immunomodulators and adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Toll-like receptor control of the adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Toll-like receptors in innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Toll-like receptor 2 mediates cellular activation by the B subunits of type II heat-labile enterotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Triacyl-lipopentapeptide adjuvants: TLR2-dependent activation of macrophages and modulation of receptor-mediated cell activation by altering acyl-moieties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Discrimination of bacterial lipoproteins by Toll-like receptor 6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

7 January 2021

Eosinophil Response to Alum Adjuvants: Involvement of T Cells in Non-Antigen-Dependent Mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

7 January 2021

Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

7 January 2021

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

7 January 2021

Vaccine adjuvants based on gamma inulin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.111

7 January 2021

10.1016/J.VACCINE.2007.01.111

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17336431